Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Barbara D CruzEdna Afonso ReisLucas Lima TôrresPâmela Santos AzevedoVânia Eloisa de AraújoBrian GodmanJuliana Álvares TeodoroPublished in: Oncology and therapy (2021)
The study highlighted and confirmed that treatment with crizotinib led to clinical improvement in PFS among patients with advanced NSCLC with ALK fusion, as previously reported. However, there was no increase in overall survival in patients with NSCLC with genetic alterations of ALK. This must be considered when reviewing and funding treatments for NSCLC patients with this mutation.